YIPF5

Across TCGA pan-cancer cohorts, YIPF5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated YIPF5 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher YIPF5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated YIPF5 expression acts as an unfavorable survival marker.

SKCM, GBM, and LUSC are the cancer types where YIPF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.382	0.784	.008	12	view →
GBM	DFS	Median	All	0.068	0.288	.003	6	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

YIPF5–SKCM (OS)

Open the SKCM breakdown →